Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 10, Issue 5, 2000, Pages 253-262

  Davidson, M H ^a   Stein, E A ^b   Hunninghake, D B ^c   Ose, L ^d   Dujovne, C A ^a   Insull Jr , W ^e   Bertolami, M ^f   Weiss, S R ^g   Kastelein, J J P ^h   Scott, R S ⁱ   Campodonico S ^j   Escobar, I D ^k   Schrott, H G ^l   Bays, H ^m   Stepanavage, M E ⁿ   Wu, M ⁿ   Tate, A C ⁿ   Melino, M R ⁿ   Kush, D ⁿ   Mercuri, M ⁿ   Mitchel, Y B ⁿ   more..

^a RADIANT RESEARCH   (United States)

^b Metab and Atherosclerosis Res Ctr   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f Intituto Dante Pazzonese de Cardiologia   (Brazil)

^g S Diego Endocr and Medical Clinic   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j Clínica Vesalio   (Peru)

^k Association Colombiana de Diabetes   (Colombia)

^l UNIVERSITY OF IOWA   (United States)

^m LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Hypercholesterolemia; Low density lipoprotein cholesterol; Simvastatin; Triglycerides

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SAFETY; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0034304746     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus JTM, Musliner TA, Olsson AG, Pyorala K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L (1996) Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156: 2085-2092
2. MAAS investigators (1994) Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344: 633-638
3. Stein E, Davidson M, Dobs A, Schrott H, Dujovne C, Bays H, Weiss S, Melino M, Stepanavage M, Mitchel Y (1998) Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol 82: 311-316
4. Ose L, Kastelein J, Scott R, Stein E, Campodonico S, Escobar J, Tate A, Corsetti L, Shahane A, Mitchel Y, Mercuri M (1998) Efficacy and six-month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr Metab Cardiovasc Dis 8: 143-151
5. Ose L, Davidson MH, Stein EA, Kastelein JJP, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB, for The World Wide Expanded Dose Simvastatin Study Group (2000) Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolemia. Clin Cardiol 23: 39-46
6. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, et al (1994) Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 15: 255-269
7. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA (1997) The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 79: 38-42
8. Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA (1999) Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol 83: 1476-1477
9. Stein S, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, Stepanavage M, Mercuri M (2000) Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 86: 406-411
10. Expert panel on detection evaluation and treatment of high blood cholesterol in adults (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269: 3015-3023
11. Krauss R, Deckelbaum R, Ernst N, Fisher E, Howard B, Knopp R, Kotchen T, Lichtenstein A, McGill H, Pearson T, Prewitt T, Stone N, Horn L, Weinberg R (1996) Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 94: 1795-1800
12. Myers GL, Cooper GR, Winn CL, Smith SJ (1989) The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 9: 105-135
13. Warnick G, Albers J (1978) A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19: 65-76
14. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR (1990) Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I. Arch Intern Med 150: 341-345
15. Santer S, Santen R, Kulin H, Demers L (1981) A model for validation of radioimmunoassay kit reagents: measurement of follitropin and lutropin in blood and urine. Clin Chem 27: 1892-1895
16. Kubasik N, Hallaver G, Brodows R (1984) Evaluation of direct solid phase radioimmunoassay for progesterone, useful for monitoring luteal function. Clin Chem 30: 284-286
17. Abbott Diagnostics (1993) Tdx System Operator's Manual. Abbott Park, IL
18. Newton WT, McGuigan JE, Jaffe BM (1970) Radioimmunoassay of peptides lacking tyrosine. J Lab Clin Med 75: 886-892
19. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD (1995) Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 91: 2274-2282
20. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453-1460
21. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H (1991) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151: 43-49
22. Parke-Davis (1999) Product circular for Lipitor (atovastatin calcium) tablets. In: Physicians' Desk Reference. Medical Economics Company, Montvale, pp. 2293-2296
23. Dobs AS, Miller S, Neri G, Weiss S, Tate AC, Shapiro DR, Musliner TA (2000) Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metab Clin Exp 49: 115-121
24. Pedersen T, Faergeman O (1999) Simvastatin seems unlikely to cause impotence (letter). Br Med J 318: 192
25. Purvis K, Tollefsrud A, Rui H, Haug E, Norseth J, Ose L, Lund H (1992) Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolemia. Eur J Clin Pharmacol 42: 61-64